Our Mission

Translating the biology of regulatory T cells (Tregs) into transformational medicines for patients with progressive multiple sclerosis and other serious autoimmune and inflammatory diseases

Who We Are

Abata was launched in 2021 by Third Rock Ventures with a $95 million Series A financing and brings together industry experts and deeply engaged pioneers in regulatory T cell (Treg) biology, T cell receptor (TCR) and antigen discovery, disease pathogenesis, and molecular and imaging biomarkers to advance the development of Treg cell therapies for serious autoimmune and inflammatory diseases.

Together, we are bringing an entirely new approach to the treatment of autoimmune disease by engineering Tregs as targeted therapies that stop immune-mediated destruction, restore homeostasis – a state of harmony – and promote repair in the affected tissues.

It’s All in the Name

Abata’s story begins with our name.

In Nyanja, a Bantu language widely spoken in southern Africa, “abata” means “tranquil,” and “ndi malo abata” translates to “it’s a quiet place.” In Esperanto, “abata” means “of an abbey,” a place of peace. “Abata” is the very essence of what our Treg cell therapies seek to do: restore tranquility, peace and harmony in the body.

Leadership

Investors

Careers with Abata

Join Our Team

If you’re ready to take a bold step in your career and challenge convention, this is your team!